{"groups":[{"description":"Daily single dose of Osimertinib 80mg","id":"FG000","title":"Osimertinib 80 mg"},{"description":"Platinum-based doublet chemotherapy","id":"FG001","title":"Chemotherapy"}],"periods":[{"dropWithdraws":[{"reasons":[{"groupId":"FG000","numSubjects":"184"},{"groupId":"FG001","numSubjects":"88"}],"type":"Death"},{"reasons":[{"groupId":"FG000","numSubjects":"7"},{"groupId":"FG001","numSubjects":"1"}],"type":"Lost to Follow-up"},{"reasons":[{"groupId":"FG000","numSubjects":"27"},{"groupId":"FG001","numSubjects":"21"}],"type":"Withdrawal by Subject"},{"reasons":[{"groupId":"FG000","numSubjects":"0"},{"groupId":"FG001","numSubjects":"1"}],"type":"Eligibility criteria not fulfilled"},{"reasons":[{"groupId":"FG000","numSubjects":"1"},{"groupId":"FG001","numSubjects":"2"}],"type":"Other reasons"}],"milestones":[{"achievements":[{"groupId":"FG000","numSubjects":"279"},{"groupId":"FG001","numSubjects":"140"}],"type":"STARTED"},{"achievements":[{"groupId":"FG000","numSubjects":"279"},{"groupId":"FG001","numSubjects":"136"}],"type":"Received Randomised Treatment Only"},{"achievements":[{"groupId":"FG000","numSubjects":"0"},{"groupId":"FG001","numSubjects":"4"}],"type":"Did Not Receive Treatment"},{"achievements":[{"groupId":"FG000","numSubjects":"0"},{"comment":"Patients randomised to chemotherapy were allowed to crossover to Osimertinib after progression","groupId":"FG001","numSubjects":"99"}],"type":"Crossed Over Osimertinib"},{"achievements":[{"groupId":"FG000","numSubjects":"60"},{"groupId":"FG001","numSubjects":"27"}],"type":"COMPLETED"},{"achievements":[{"groupId":"FG000","numSubjects":"219"},{"groupId":"FG001","numSubjects":"113"}],"type":"NOT COMPLETED"}],"title":"Overall Study"}],"recruitmentDetails":"First patient dosed: 20 August 2014. Data cut off: 15 March 2019. Open for enrolment at 145 study centres, 126 centres in 17 countries randomised patients to treatment. Following the final OS analysis, patients were permitted to continue to receive treatment if, in the investigator's opinion, they were continuing to receive benefit from treatment. The last patient completed the study on the 15 December 2023"}